WuXi XDC Cayman Inc. provided earnings guidance for the year ended December 31, 2023. It is expected that the Group will record an increase of over 100% in revenue; an increase of over 80% in net profit; and an increase of over 100% in adjusted net profit, as compared with those for the corresponding period of last year. The Company considers that such expected increase was primarily attributable to the continuous active development of antibody-drug conjugate (``ADC'') industry and the Group's unique competitive strengths in winning projects.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
15.04 USD | +4.16% | -3.47% | -53.00% |
Jun. 24 | WuXi XDC Cayman Inc.(SEHK:2268) added to S&P Global BMI Index | CI |
May. 17 | Certain Shares of WuXi XDC Cayman Inc. are subject to a Lock-Up Agreement Ending on 15-MAY-2024. | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-53.00% | 2.31B | |
+55.35% | 815B | |
+32.24% | 597B | |
-0.10% | 377B | |
+15.47% | 319B | |
+13.10% | 310B | |
+16.57% | 247B | |
+14.59% | 228B | |
+16.54% | 180B | |
+4.31% | 170B |
- Stock Market
- Equities
- 2268 Stock
- News WuXi XDC Cayman Inc.
- WuXi XDC Cayman Inc. Provides Earnings Guidance for the Year Ended December 31, 2023